This Protein Could Rewire Heart Disease Risk

An anatomical heart illustration next to a blood pressure monitor

Scientists found a protein inside your liver that controls how much “bad” cholesterol gets packaged into your blood — and when they tweaked it in mice, it rewired the entire equation of heart disease risk.

Story Snapshot

Researchers at UT Southwestern identified a protein called HELZ2 that degrades the messenger RNA responsible for producing apolipoprotein B, the core protein in harmful cholesterol particles.
A specific mutation nicknamed “Colby” supercharges HELZ2’s activity, sharply reducing apoB expression and protecting mice against atherosclerosis.
The mechanism cuts both ways: turning HELZ2 up lowers blood cholesterol but raises liver fat, and turning it down does the reverse.
All evidence so far is from mouse models, and no human trials or approved therapies exist yet.

Why ApoB Is the Cholesterol Number That Actually Matters

Most people know their LDL cholesterol number. Far fewer have heard of apolipoprotein B, or apoB, yet researchers have argued for years that apoB is the more accurate marker for cardiovascular risk. ^[4] Every harmful cholesterol particle — low-density lipoprotein, very low-density lipoprotein, lipoprotein(a) — carries exactly one apoB protein. Count the apoB particles, and you know precisely how many dangerous vehicles are circulating in your bloodstream. That single number predicts heart attack risk better than LDL cholesterol alone, which is why the HELZ2 discovery landed with such force in the cardiology world.

The liver manufactures and secretes these apoB-carrying particles constantly. Anything that controls how many get made sits at an extraordinarily powerful leverage point. That is exactly where HELZ2 operates — not on the cholesterol molecule itself, but on the genetic instructions the liver uses to build the apoB protein in the first place. ^[1]

How HELZ2 Dismantles the Blueprint for Bad Cholesterol

HELZ2 is a helicase, a class of proteins that unwind and process RNA strands. Researchers publishing in the journal Circulation in early 2026 demonstrated that HELZ2 physically binds to Apob messenger RNA — the molecular blueprint the liver reads to produce apoB — and degrades it before the protein can be assembled. ^[1] Less messenger RNA means less apoB protein, which means fewer harmful cholesterol particles released into circulation. The mechanism is elegant precisely because it targets the instruction manual rather than the finished product.

The team discovered a gain-of-function mutation they named “Colby,” designated L1833P, that amplifies HELZ2’s helicase activity. ^[1] Mice carrying a single copy of the Colby mutation showed markedly reduced apoB expression and, critically, significant protection against atherosclerosis in two separate mouse models engineered to develop arterial plaque. ^[1] When researchers went the other direction — breeding mice with no functional HELZ2 — apoB messenger RNA levels rose and liver triglycerides fell on a high-fat diet, confirming the causal relationship runs in both directions. ^[1]

The Tradeoff That Complicates the Celebration

Here is where the story gets genuinely complicated, and where the breathless “master switch” coverage deserves a pause. Increasing HELZ2 activity lowers cholesterol in the blood but increases fat accumulation in the liver. ^[2] Decreasing it does the reverse. That is not a minor footnote — it is a fundamental biological tradeoff baked into the mechanism itself. A therapy designed to ramp up HELZ2 to protect arteries could simultaneously worsen fatty liver disease, which is already a growing epidemic tied to metabolic dysfunction. Researchers and physicians will need to square that circle before this becomes anything resembling a drug.

Scientists at UT Southwestern have uncovered a surprising new “master switch” that helps control how much cholesterol the liver sends into the bloodstream. The newly identified protein, HELZ2, works by shutting down the genetic instructions needed to produhttps://t.co/EXfGVc2NWN

— Michael W. Deem (@Michael_W_Deem) May 25, 2026

Dr. Zhang’s team at UT Southwestern acknowledges the tradeoff directly, describing genetic or pharmacological modulation of HELZ2 as a “promising therapeutic strategy” rather than a solved problem. ^[1] That language is honest and appropriate for the stage of the science. The concern is that institutional press releases and secondary science coverage tend to compress “promising strategy in mice” into “scientists discover hidden liver switch,” which are very different claims separated by years of human validation work, if it ever arrives at all.

What Has to Happen Before This Changes Your Doctor Visit

Every piece of evidence supporting the HELZ2 mechanism comes from mouse models. ^[1] No human liver tissue studies, no genetic association data from large human cohorts, and no clinical trials exist yet. The path from a mouse mutation called Colby to a pill you swallow requires demonstrating the same mechanism operates in human hepatocytes, that modulating it in people produces the expected changes in apoB and liver fat, that a drug can target HELZ2 selectively, and that the safety profile is acceptable across diverse patient populations. Each of those steps has historically taken a decade or more, and many promising mouse findings never survive the translation. ^[5]

None of that diminishes what the UT Southwestern team actually accomplished. Publishing a peer-reviewed mechanistic discovery in Circulation, identifying a specific mutation that protects against atherosclerosis in animal models, and mapping a previously unknown regulatory pathway for apoB production is genuinely significant science. ^[3] The finding earns serious attention from the cardiovascular research community. What it does not yet earn is the assumption that a new cholesterol therapy is around the corner. The science is real. The timeline is not.